Mark Bower
YOU?
Author Swipe
View article: STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma Open
Background Kaposi sarcoma (KS) is a mesenchymal malignancy induced by human herpes virus-8 (HHV-8). Whilst combined anti-retroviral therapy (cART) has substantially reduced the incidence of KS in people living with HIV (PLWH), KS remains t…
View article: Hepatocellular carcinoma in people living with HIV
Hepatocellular carcinoma in people living with HIV Open
People living with HIV (PLWH) carry a higher risk of developing chronic liver disease and hepatocellular carcinoma (HCC). This relates to shared transmission pathways of HIV and viral hepatitis and a plethora of direct and indirect effects…
View article: Primary Effusion Lymphoma Prognostic Score (<scp>PEL</scp>‐<scp>PS</scp>): A Validated International Prognostic Score in <scp>HIV</scp>‐Associated Primary Effusion Lymphoma
Primary Effusion Lymphoma Prognostic Score (<span>PEL</span>‐<span>PS</span>): A Validated International Prognostic Score in <span>HIV</span>‐Associated Primary Effusion Lymphoma Open
Primary effusion lymphoma (PEL) is an HIV‐associated B‐cell non‐Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is thought to be poor compared to other HIV‐as…
View article: Clinical management of human herpesvirus-8-related illnesses in solid organ transplant recipients
Clinical management of human herpesvirus-8-related illnesses in solid organ transplant recipients Open
In solid organ transplant recipients (SOTRs), the oncogenic virus human herpesvirus-8 (HHV-8) also named Kaposi sarcoma herpesvirus (KSHV) causes four clinical diseases: Kaposi Sarcoma, Primary Effusion Lymphoma, Multicentric Castleman Dis…
View article: Outcomes of Lymphoma Patients Admitted to the ICU Are Not Influenced by HIV Status: A Retrospective, Observational Cohort Study
Outcomes of Lymphoma Patients Admitted to the ICU Are Not Influenced by HIV Status: A Retrospective, Observational Cohort Study Open
Background: Patients with lymphoma may require intensive care (ICU) because of disease- or treatment-related complications. The lymphoma–HIV interaction complicates management, but whether outcomes are worse in these patients, when critica…
View article: Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Open
International audience
View article: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up Open
Highlights This EHA–ESMO Clinical Practice Guideline provides key recommendations for managing HIV‐associated lymphomas. The guideline covers clinical, imaging and pathological diagnosis; staging and risk assessment; treatment and follow‐u…
View article: MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study Open
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHO…
View article: Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry Open
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific pop…
View article: Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry Open
In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.
View article: The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma Open
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospec…
View article: The Pre-Implementation Phase of a Project Seeking to Deliver a Community-Based CVD Prevention Intervention (SPICES-Sussex): A Qualitative Study Exploring Views and Experience Relating to Intervention Development
The Pre-Implementation Phase of a Project Seeking to Deliver a Community-Based CVD Prevention Intervention (SPICES-Sussex): A Qualitative Study Exploring Views and Experience Relating to Intervention Development Open
Background. Community-led health care interventions may be an effective way to tackle cardiovascular disease (CVD) risk factors, especially in materially deprived communities where health care resources are stretched and engagement with in…
View article: Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium Open
PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use o…
View article: 265P UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer
265P UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer Open
The transgender population face inequalities throughout the cancer pathway. Much of this stems from a lack of access to specialist knowledge of gender-affirming care and how it intersects with cancer. Breast cancer care in particular prese…
View article: Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
Supplementary Tables and Figures
View article: Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
Supplementary Tables and Figures
View article: Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as …
View article: Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer Open
The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as …
View article: Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma Open
Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlight…
View article: Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer Open
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included …
View article: 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium
437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium Open
Background Due to limited inclusion of PLWH in most ICI clinical trials, there is a paucity of data evaluating their safety and efficacy in this unique population, especially among PLWH and metastatic NSCLC. Methods In this retrospective, …
View article: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries Open
Background As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. Methods In a joint analysis …